600518.SS
600518.SS
CNE0000017M1
KANGMEI PHARMACEUTICAL CO LTD
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 70/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±34.2% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.6x).

Beta (Market Relation)
0.58x
Defensive
Volatility (5Y p.a.)
34.2% p.a.
5-Year Horizon
Max Drawdown (5Y)
-76.1%
5-Year Horizon
Sharpe Ratio
-0.70
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -33.8%
3 Years 31.9% -58.0% -0.39 -10%
5 Years 34.2% -76.1% -0.7 -20.8%
10 Years 44.3% -95.7% -0.56 -22.3%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (34.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -95.7% in the extended horizon.
ende